Newsroom

Chapter on 99mTc-maraciclatide Published in the 2025 EANM Technologists’ Guide

Serac Healthcare highlights that a chapter on ^99mTc-maraciclatide as an imaging agent for diagnosing endometriosis was published in the European Association of Nuclear Medicine’s Technologists' Guide 2025, which launched at EANM’s annual congress this week.

Molecular Imaging of Interstitial Lung Disease with Maraciclatide: PREDICT-ILD Data Presented at ERS

Serac Healthcare and the University of Exeter, today announce the first findings from a study evaluating a novel molecular imaging agent, ^99mTc-maraciclatide, as an imaging marker for interstitial lung disease evaluation. The data will be presented at the European Respiratory Society conference taking place from 27 September to 1 October in Amsterdam.

Professor Alan Perkins Awarded MBE for Services to Patient Care and Clinical Science

Serac Life Sciences, the parent company of molecular imaging businesses Serac Healthcare Ltd and Serac Imaging Systems Ltd,  announce that their Scientific Advisor, Professor Alan Perkins, has been awarded a Member of the Order of the British Empire (MBE) in the King’s Birthday Honours in recognition of his outstanding services to patient care and clinical science.

Primary Endpoint Met in the DETECT Endometriosis Imaging Study

Headline Data Presented at the World Congress on Endometriosis

Serac Healthcare Limited and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that the primary endpoint has been met in the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) Phase II imaging study.

Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - Positive Feedback on Phase III Trial Design -  

Serac Healthcare Limited today announced positive feedback from its End of Phase II Meeting with the US Food and Drug Administration (FDA) for the development of ^99mTc-maraciclatide as a diagnostic agent for use with single-photon emission computed tomography (SPECT-CT) for the visualisation and diagnosis of superficial peritoneal endometriosis (SPE) in women aged 16 years of age and older.

DETECT abstract accepted at World Congress on Endometriosis 2025

An abstract on the “Detecting Endometriosis integrins using technetium-99m” (DETECT)  imaging study, has been accepted for oral presentation at the prestigious 16^th World Congress on Endometriosis taking place from 21-24 May in Sydney, Australia.